The Adenoviral Core (C) will provide necessary support for the creation, selection, characterization, production, and purification of the recombinant adenovirus required in subprojects 2, 3 and 4. The expertise for directing the core facility will be supplied by Mark Sussman, Ph.D.. This core will provide a variety of support services including: Production of the shuttle vector plasmid DNA (for distribution to investigators) and genomic DNA used for recombination experiments. 1. Maintenance of human embryonic kidney 293 cells permissive for adenoviral replication. 2. Cotransfection of transgene shuttle vector and adenoviral genomic DNA into 293 cells. 3. Monitoring cultures for DNA recombination resulting in adenoviral production. 4. Amplification of recombinant cultures. 5. Immunoblot assay to confirm expression of the transgene of interest (northern blots analyses will be used if antibodies are unavailable). 6. Clonal selection of confirmed recombinant viruses producing protein. 7. Purification and concentration of recombinant adenoviruses. 8. Titration of stocks for determination of plaque forming unit (pfu) levels. 9. Repository service for storage and cataloging of low passage viral stocks to serve as a backup for viral stocks given to investigators.Preparation of neonatal rat cardiomyocyte cultures.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL069779-01
Application #
6606602
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2002-06-06
Project End
2007-04-30
Budget Start
2002-06-06
Budget End
2003-04-30
Support Year
1
Fiscal Year
2002
Total Cost
$305,975
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Singh, Sonia R; Robbins, Jeffrey (2018) Desmin and Cardiac Disease: An Unfolding Story. Circ Res 122:1324-1326
Lowey, Susan; Bretton, Vera; Joel, Peteranne B et al. (2018) Hypertrophic cardiomyopathy R403Q mutation in rabbit ?-myosin reduces contractile function at the molecular and myofibrillar levels. Proc Natl Acad Sci U S A 115:11238-11243
Valiente-Alandi, IƱigo; Potter, Sarah J; Salvador, Ane M et al. (2018) Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure. Circulation 138:1236-1252
Meng, Qinghang; Bhandary, Bidur; Bhuiyan, Md Shenuarin et al. (2018) Myofibroblast-Specific TGF? Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy. Circ Res 123:1285-1297
Singh, Sonia R; Zech, Antonia T L; Geertz, Birgit et al. (2017) Activation of Autophagy Ameliorates Cardiomyopathy in Mybpc3-Targeted Knockin Mice. Circ Heart Fail 10:
Xiang, Fu-Li; Fang, Ming; Yutzey, Katherine E (2017) Loss of ?-catenin in resident cardiac fibroblasts attenuates fibrosis induced by pressure overload in mice. Nat Commun 8:712
Kamal, Fadia A; Travers, Joshua G; Schafer, Allison E et al. (2017) G Protein-Coupled Receptor-G-Protein ??-Subunit Signaling Mediates Renal Dysfunction and Fibrosis in Heart Failure. J Am Soc Nephrol 28:197-208
Khalil, Hadi; Kanisicak, Onur; Prasad, Vikram et al. (2017) Fibroblast-specific TGF-?-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest 127:3770-3783
McLendon, Patrick M; Davis, Gregory; Gulick, James et al. (2017) An Unbiased High-Throughput Screen to Identify Novel Effectors That Impact on Cardiomyocyte Aggregate Levels. Circ Res 121:604-616
Rudomanova, Valeria; Blaxall, Burns C (2017) Targeting GPCR-G??-GRK2 signaling as a novel strategy for treating cardiorenal pathologies. Biochim Biophys Acta Mol Basis Dis 1863:1883-1892

Showing the most recent 10 out of 131 publications